Although AZD8055 was initially able to inhibit the activity of mTOR complexes 1/2 and the Akt signaling pathway, this inhibition was only transient; pancreatic cancer cells rapidly regained tolerance to the drug with the activation of EGFR and its downstream kinases (97). Here, EGFR is linked to pancreatic neoplasm.